• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

勘误：自然杀伤细胞来源的外泌体miR-3607-3p通过靶向IL-26抑制胰腺癌进展。

Corrigendum: Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26.

作者信息

Sun Hongwei, Shi Keqing, Qi Kai, Kong Hongru, Zhang Jie, Dai Shengjie, Ye Wen, Deng Tuo, He Qiye, Zhou Mengtao

机构信息

Department of Hepatobiliary Surgery, Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of ZheJiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of ZheJiang Province, Center of Precision Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

出版信息

Front Immunol. 2020 Feb 21;11:277. doi: 10.3389/fimmu.2020.00277. eCollection 2020.

DOI:10.3389/fimmu.2020.00277
PMID:32153584
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7047058/
Abstract

[This corrects the article DOI: 10.3389/fimmu.2019.02819.].

摘要

[本文更正了文章DOI：10.3389/fimmu.2019.02819。]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90b4/7047058/3a3845037181/fimmu-11-00277-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90b4/7047058/e9334e49d003/fimmu-11-00277-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90b4/7047058/3a3845037181/fimmu-11-00277-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90b4/7047058/e9334e49d003/fimmu-11-00277-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90b4/7047058/3a3845037181/fimmu-11-00277-g0002.jpg

相似文献

1
Corrigendum: Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26.勘误：自然杀伤细胞来源的外泌体miR-3607-3p通过靶向IL-26抑制胰腺癌进展。
Front Immunol. 2020 Feb 21;11:277. doi: 10.3389/fimmu.2020.00277. eCollection 2020.
2
Retraction: Corrigendum: Natural killer cell-derived exosomal miR-3607-3p inhibits pancreatic cancer progression by targeting IL-26.撤稿声明：勘误：自然杀伤细胞来源的外泌体miR-3607-3p通过靶向IL-26抑制胰腺癌进展。
Front Immunol. 2024 Aug 19;15:1480131. doi: 10.3389/fimmu.2024.1480131. eCollection 2024.
3
Retraction: Natural killer cell-derived exosomal miR-3607-3p inhibits pancreatic cancer progression by targeting IL-26.撤回声明：自然杀伤细胞衍生的外泌体miR-3607-3p通过靶向IL-26抑制胰腺癌进展。
Front Immunol. 2024 Aug 19;15:1480124. doi: 10.3389/fimmu.2024.1480124. eCollection 2024.
4
Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26.自然杀伤细胞衍生的外泌体 miR-3607-3p 通过靶向 IL-26 抑制胰腺癌进展。
Front Immunol. 2019 Dec 11;10:2819. doi: 10.3389/fimmu.2019.02819. eCollection 2019.
5
Exosomal miR-485-3p derived from pancreatic ductal epithelial cells inhibits pancreatic cancer metastasis through targeting PAK1.胰腺导管上皮细胞来源的外泌体 miR-485-3p 通过靶向 PAK1 抑制胰腺癌转移。
Chin Med J (Engl). 2022 Oct 5;135(19):2326-2337. doi: 10.1097/CM9.0000000000002154.
6
Bone Marrow Mesenchymal Stem Cell-Derived Exosomal MicroRNA-126-3p Inhibits Pancreatic Cancer Development by Targeting ADAM9.骨髓间充质干细胞衍生的外泌体微小RNA-126-3p通过靶向ADAM9抑制胰腺癌发展。
Mol Ther Nucleic Acids. 2019 Jun 7;16:229-245. doi: 10.1016/j.omtn.2019.02.022. Epub 2019 Mar 1.
7
Retracted Article: Exosomal miR-25-3p derived from hypoxia tumor mediates IL-6 secretion and stimulates cell viability and migration in breast cancer.撤稿文章：缺氧肿瘤来源的外泌体miR-25-3p介导白细胞介素-6分泌并刺激乳腺癌细胞的活力和迁移。
RSC Adv. 2019 Jan 11;9(3):1451-1459. doi: 10.1039/c8ra06750c. eCollection 2019 Jan 9.
8
Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.巨噬细胞衍生的外泌体 microRNA-501-3p 通过 TGFBR3 介导的 TGF-β 信号通路促进胰腺导管腺癌的进展。
J Exp Clin Cancer Res. 2019 Jul 15;38(1):310. doi: 10.1186/s13046-019-1313-x.
9
M2 macrophage-derived exosomal miR-193b-3p promotes progression and glutamine uptake of pancreatic cancer by targeting TRIM62.M2 巨噬细胞衍生的外泌体 miR-193b-3p 通过靶向 TRIM62 促进胰腺癌的进展和谷氨酰胺摄取。
Biol Direct. 2023 Jan 11;18(1):1. doi: 10.1186/s13062-023-00356-y.
10
Exosomal MiR-423-3p inhibits macrophage M2 polarization to suppress the malignant progression of cervical cancer.外泌体 miR-423-3p 抑制巨噬细胞 M2 极化以抑制宫颈癌的恶性进展。
Pathol Res Pract. 2022 Jul;235:153882. doi: 10.1016/j.prp.2022.153882. Epub 2022 Apr 6.

引用本文的文献

1
TCR-T cell therapy for solid tumors: challenges and emerging solutions.用于实体瘤的TCR-T细胞疗法：挑战与新出现的解决方案
Front Pharmacol. 2025 Mar 10;16:1493346. doi: 10.3389/fphar.2025.1493346. eCollection 2025.
2
Extracellular vesicles: emerging anti-cancer drugs and advanced functionalization platforms for cancer therapy.细胞外囊泡：新兴的抗癌药物和先进的癌症治疗功能化平台。
Drug Deliv. 2022 Dec;29(1):2513-2538. doi: 10.1080/10717544.2022.2104404.